U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H33ClN2O5S.ClH
Molecular Weight 461.444
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLINDAMYCIN HYDROCHLORIDE

SMILES

Cl.CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O

InChI

InChIKey=AUODDLQVRAJAJM-XJQDNNTCSA-N
InChI=1S/C18H33ClN2O5S.ClH/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4;/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25);1H/t9-,10+,11-,12+,13-,14+,15+,16+,18+;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H33ClN2O5S
Molecular Weight 424.983
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes; Skin and skin structure infections; Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes; Intra-abdominal infections; Septicemia; Bone and joint infections. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents

CNS Activity

Originator

Approval Year

TargetsConditions
PubMed

PubMed

TitleDatePubMed
A simple, efficient and inexpensive program for preventing prematurity.
2001
Occurrence of metronidazole and imipenem resistance among Bacteroides fragilis group clinical isolates in Hungary.
2001
Superantigen antagonist peptides.
2001
Streptococcal toxic shock syndrome revealed by a peritonitis. Case report and review of the literature.
2001
Lemierre's syndrome with spondylitis and pulmonary and gluteal abscesses associated with Mycoplasma pneumoniae pneumonia.
2001 Apr
Clinical features of patients with invasive Eikenella corrodens infections and microbiological characteristics of the causative isolates.
2001 Apr
Thoracic spondylitis mimicking idiopathic scoliosis: a case report.
2001 Apr
Activation of clindamycin phosphate by human skin.
2001 Apr
Clindamycin suspension and endocarditis prophylaxis.
2001 Apr 28
Laparoscopic management of adnexal masses.
2001 Apr-Jun
Successful treatment regime for folliculitis decalvans despite uncertainty of all aetiological factors.
2001 Feb
Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia.
2001 Feb
Dermatopharmacology of a new combination gel formulation for the topical treatment of acne.
2001 Feb
Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction.
2001 Feb
The development of antibiotic resistance in Propionibacterium acnes.
2001 Feb
Anti-anaerobic activity of antibacterial agents.
2001 Feb
Clostridium difficile--Associated diarrhea: A review.
2001 Feb 26
[Guidelines for antibiotic prophylaxis of bacterial endocarditis in patients undergoing dental therapy].
2001 Jan
Clonal relationships among penicillin-susceptible, multiresistant serotype 6B Streptococcus pneumoniae isolates recovered in Greece and France.
2001 Jan
Emerging erythromycin resistance among group B streptococci in Korea.
2001 Jan
[Prevention of endocarditis within the scope of ENT interventions. Current recommendations].
2001 Jan
Clostridium difficile colitis following antibiotic prophylaxis for dental procedures.
2001 Jan
Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents.
2001 Jul
A rare case of primary group A streptococcal peritonitis.
2001 Jul
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.
2001 Jul
Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads.
2001 Jul
Cutaneous botryomycosis of the cervicofacial region.
2001 Jul
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae.
2001 Jun
The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea.
2001 Jun
Eikenella corrodens: an unusual cause of severe parapneumonic infection and empyema in immunocompetent patients.
2001 Jun
[Chronic osteomyelitis of the ilium after autologous bone harvesting in Albers-Schonberg osteopetrosis. A case report].
2001 Jun
Bilateral peritonsillar abscess: case report and presentation of its clinical appearance.
2001 Jun
Transfusion-transmitted babesiosis in Ontario: first reported case in Canada.
2001 Jun 12
A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia.
2001 Jun 25
[Antibiotic prophylaxis in oncologic pharyngolaryngeal surgery: ceftriaxone versus clindamycin and gentamycin].
2001 Mar
Antibiotic susceptibility of Clostridium difficile isolates from adult patients at two Jamaican hospitals. Clinical and epidemiological implications.
2001 Mar
[Ocular parasitoses and mycoses: cases diagnosed in the Central University Hospital of Sfax between 1996 and 1999].
2001 Mar
A 2-step non-surgical procedure and systemic antibiotics in the treatment of rapidly progressive periodontitis.
2001 Mar
Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae isolated from pigs with swine erysipelas in Japan, 1988-1998.
2001 Mar
Comparative in-vitro activity of trovafloxacin and other related drugs against isolates of streptococcus oralis.
2001 Mar
Antibiotic-resistant bacteria in pediatric chronic sinusitis.
2001 Mar
Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec, Canada.
2001 Mar
[Dermo-hypodermitis and necrotizing fasciitis].
2001 Mar 31
Serotyping and antimicrobial susceptibility of group B Streptococcus over an eight-year period in southern Taiwan.
2001 May
Effect of clindamycin therapy on phagocytic and oxidative activity profiles of spleen mononuclear cells in Babesia rodhaini-infected mice.
2001 May
Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial.
2001 May
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.
2001 May 15
Sensitive and specific determination of clindamycin in human serum and bone tissue applying liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry.
2001 May 5
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.
2001 May-Jun
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification.
2001 Spring
Patents

Sample Use Guides

In Vivo Use Guide
150 to 300 mg every 6 hours (Serious infections), 300 to 450 mg every 6 hours (More severe infections), 8 to 16 mg/kg/day divided into three or four equal doses (Serious infections in pediatric patients), 16 to 20 mg/kg/day divided into three or four equal doses (More severe infections in pediatric patients).
Route of Administration: Topical; Vaginal; Intramuscular; Intravenous
In Vitro Use Guide
MIC=0.03-0.12 ug/ml (Aerobic Pathogens), MIC=0.06-0.25 ug/ml (Anaerobes).
Substance Class Chemical
Created
by admin
on Tue Oct 22 00:37:02 UTC 2019
Edited
by admin
on Tue Oct 22 00:37:02 UTC 2019
Record UNII
T20OQ1YN1W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLINDAMYCIN HYDROCHLORIDE
EP   GREEN BOOK   MART.   MI   ORANGE BOOK   USP   VANDF   WHO-DD  
Common Name English
ANTIROBE
Brand Name English
SOBELIN
Brand Name English
CLINDAMYCIN HCL
Common Name English
CLINDAMYCIN HYDROCHLORIDE [GREEN BOOK]
Common Name English
CLINDAMYCIN HYDROCHLORIDE [WHO-DD]
Common Name English
DALACIN C
Brand Name English
L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE, METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(((1-METHYL-4-PROPYL-2-PYRROLIDINYL)CARBONYL)AMINO)-1-THIO-,(2S-TRANS)-, MONOHYDROCHLORIDE
Common Name English
CLINDAMYCIN HYDROCHLORIDE [VANDF]
Common Name English
CLINSOL
Brand Name English
CLINTABS
Brand Name English
CLINDAMYCIN HYDROCHLORIDE [USP]
Common Name English
CLINDAMYCIN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
CLINDAMYCIN HYDROCHLORIDE [MI]
Common Name English
CLINDAMYCIN HYDROCHLORIDE [MART.]
Common Name English
CLINDAMYCIN HYDROCHLORIDE [JAN]
Common Name English
CLINDAMYCIN (AS HYDROCHLORIDE)
Common Name English
CLINDAMYCIN HYDROCHLORIDE ANHYDROUS
Common Name English
METHYL 7-CHLORO-6,7,8-TRIDEOXY-6-(1-METHYL-TRANS-4-PROPYL-L-2-PYRROLIDINECARBOXAMIDO)-1-THIO-L-THREO-.ALPHA.-D-GALACTO-OCTOPYRANOSIDE MONOHYDROCHLORIDE
Common Name English
CLINDAMYCIN HYDROCHLORIDE [EP]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 213405
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
NCI_THESAURUS C82922
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
Code System Code Type Description
CAS
21462-39-5
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
NCI_THESAURUS
C47977
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
EVMPD
SUB127118
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
PUBCHEM
16051951
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
ChEMBL
CHEMBL1753
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
ECHA (EC/EINECS)
244-398-6
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
RXCUI
81982
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY RxNorm
EVMPD
SUB01342MIG
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
MERCK INDEX
M3624
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY Merck Index
EPA CompTox
21462-39-5
Created by admin on Tue Oct 22 00:37:02 UTC 2019 , Edited by admin on Tue Oct 22 00:37:02 UTC 2019
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY